Results 121 to 130 of about 114,692 (269)

A multicentre registry of hospitalized patients with acute and chronic heart failure: Study design of the H2‐registry

open access: yesESC Heart Failure, EarlyView.
The H2‐Registry: overview, first results and outlook. Abstract Aims Heart failure (HF) is a highly prevalent condition affecting 1–3% of the adult population in Europe. Despite landmark improvements in HF care over the last two decades, hospitalization and mortality rates remain relatively high.
Johannes Leiner   +15 more
wiley   +1 more source

Utilizing AI and Social Media Analytics to Discover Adverse Side Effects of GLP-1 Receptor Agonists [PDF]

open access: yesarXiv
Adverse side effects (ASEs) of drugs, revealed after FDA approval, pose a threat to patient safety. To promptly detect overlooked ASEs, we developed a digital health methodology capable of analyzing massive public data from social media, published clinical research, manufacturers' reports, and ChatGPT.
arxiv  

Registries on transcatheter edge‐to‐edge repair in heart failure: Current evidence and future perspectives

open access: yesEuropean Journal of Heart Failure, EarlyView.
Clinical evidence in transcatheter edge‐to‐edge valve repair. EF, ejection fraction; eGFR, estimated glomerular filtration rate; EROA, effective regurgitant orifice area; GDMT, guideline‐directed medical therapy; HF, heart failure; HHF, hospitalization for heart failure; LVEDV, left ventricular end‐diastolic volume; MR, mitral regurgitation; MVARC ...
Gianluigi Savarese   +13 more
wiley   +1 more source

The immunological reactivity and biological activity of synthetic glucagon [PDF]

open access: bronze, 1969
K. F. Weinges   +4 more
openalex   +1 more source

How to handle polypharmacy in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC

open access: yesEuropean Journal of Heart Failure, EarlyView.
Linking guideline‐directed medical therapy (GDMT) implementation and appropriate polypharmacy management in heart failure (HF). Polypharmacy can represent a barrier to the proper implementation of life‐prolonging GDMT for HF. A reasonable balance between the optimization of GDMT and avoiding inappropriate polypharmacy is mandatory in the contemporary ...
Davide Stolfo   +27 more
wiley   +1 more source

Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: A hidden treasure 二甲双胍和生长分化因子15 (GDF15)在2型糖尿病中的作用:一个隐藏的宝藏

open access: yesJournal of Diabetes, Volume 14, Issue 12, Page 806-814, December 2022., 2022
Highlights Metformin activates GDF15 expression, which reduces appetite with induction of weight loss in both diabetic and non‐diabetic patients. GDF15 level is linked and correlated with the progression of diabetic complications including thrombosis, diabetic nephropathy, diabetic neuropathy, and diabetic retinopathy. Abstract Type 2 diabetes mellitus
Hayder M. Al‐kuraishy   +8 more
wiley   +1 more source

Cardioprotective effects of semaglutide on isolated human ventricular myocardium

open access: yesEuropean Journal of Heart Failure, EarlyView.
Semaglutide reduces late sodium current (INa) and diastolic calcium (Ca) sparks in human cardiomyocytes from aortic stenosis (AS) and end‐stage heart failure with reduced ejection fraction (HFrEF) patients, thereby increasing Ca transients. Improved Ca storage may underly the enhanced contractility of human cardiomyocytes upon semaglutide.
Thomas Krammer   +16 more
wiley   +1 more source

Structural evidence for glucagon producing cells in the intestinal mucosa of the rat [PDF]

open access: bronze, 1968
Lelio Orci   +4 more
openalex   +1 more source

Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial

open access: yesEuropean Journal of Heart Failure, EarlyView.
Finerenone and glycaemic status in patients with heart failure with mildly reduced/preserved ejection fraction. CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; RR, rate ratio. Abstract Aims The efficacy and safety of the non‐steroidal mineralocorticoid receptor antagonist, finerenone, have not been examined in patients
Jawad H. Butt   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy